Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod

Overview of attention for article published in Drug Design, Development and Therapy, June 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 1 blog post.

How much will the MS DMT market shrink by when fingolimod comes off patent? #MSBlog #MSResearch"Unlike biological, or protein-bas…